Literature DB >> 26568392

A Girl with Idiopathic Epilepsy Showing Forced Normalization after Levetiracetam Administration.

Yasuhiko Kawakami1, Tetsuya Okazaki, Masato Takase, Osamu Fujino, Yasuhiko Itoh.   

Abstract

BACKGROUND: Forced normalization has been reported in association with almost all anti-epileptic drugs. PATIENT: We report on a 9-year-old girl with idiopathic epilepsy who showed forced normalization after administration of levetiracetam (LEV). She initially presented with generalized tonic-clonic seizures when she was 4 years old. Diffuse sharp and slow wave complexes (SWCs) were observed on electroencephalography (EEG). We prescribed sodium valproate (VPA) and benzodiazepines, but the seizures and EEG findings worsened gradually. Although subsequent administration of LEV stopped the seizures, the patient became subject to episodes of rage and violent behavior. Forced normalization was confirmed by the disappearance of SWCs on EEG. We reduced the dose of LEV and tried in various ways to resolve the situation, but finally we had to abandon LEV.
CONCLUSIONS: To the best of our knowledge, this is the first report of a patient with idiopathic epilepsy but without disabilities in everyday life showing forced normalization associated with LEV administration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26568392     DOI: 10.1272/jnms.82.250

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  2 in total

Review 1.  Effects of antiseizure medications on alternative psychosis and strategies for their application.

Authors:  Yin Yan; Jun-Hong Wu; Xiao-Yan Peng; Xue-Feng Wang
Journal:  World J Psychiatry       Date:  2022-04-19

2.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.